Cann Group (CAN) Stock Overview
Engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CAN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cann Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.014 |
| 52 Week High | AU$0.059 |
| 52 Week Low | AU$0.01 |
| Beta | 1.07 |
| 1 Month Change | 27.27% |
| 3 Month Change | -6.67% |
| 1 Year Change | -65.00% |
| 3 Year Change | -93.91% |
| 5 Year Change | -95.76% |
| Change since IPO | -97.83% |
Recent News & Updates
Recent updates
Cann Group Limited's (ASX:CAN) Share Price Boosted 36% But Its Business Prospects Need A Lift Too
Jul 20
Investors Aren't Buying Cann Group Limited's (ASX:CAN) Revenues
Jun 02The Market Doesn't Like What It Sees From Cann Group Limited's (ASX:CAN) Revenues Yet
Jan 31Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%
Sep 24Cann Group Limited's (ASX:CAN) Low P/S No Reason For Excitement
Jun 04A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share Price
Dec 27Cann Group (ASX:CAN) Is Making Moderate Use Of Debt
May 18Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For Now
Nov 03Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn Situation
Feb 23What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Nov 25
One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To Be
Nov 25Shareholder Returns
| CAN | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.2% |
| 1Y | -65.0% | -1.1% | 9.9% |
Return vs Industry: CAN underperformed the Australian Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: CAN underperformed the Australian Market which returned 10.8% over the past year.
Price Volatility
| CAN volatility | |
|---|---|
| CAN Average Weekly Movement | 23.0% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 20.3% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: CAN's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: CAN's weekly volatility has increased from 16% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Jenni Pilcher | www.canngrouplimited.com |
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
Cann Group Limited Fundamentals Summary
| CAN fundamental statistics | |
|---|---|
| Market cap | AU$9.85m |
| Earnings (TTM) | -AU$22.34m |
| Revenue (TTM) | AU$13.25m |
Is CAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAN income statement (TTM) | |
|---|---|
| Revenue | AU$13.25m |
| Cost of Revenue | AU$8.10m |
| Gross Profit | AU$5.15m |
| Other Expenses | AU$27.50m |
| Earnings | -AU$22.34m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 38.88% |
| Net Profit Margin | -168.60% |
| Debt/Equity Ratio | -2,718.0% |
How did CAN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/22 11:29 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cann Group Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cameron Bell | Canaccord Genuity |
| Paul Jensz | PAC Partners Securities Pty. Ltd. |